Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

10 Jul 2008 07:00

RNS Number : 7470Y
Angle PLC
10 July 2008
 



For Immediate Release

10 July 2008

ANGLE plc

ANGLE Long-term Management Contract Win

Contract Value Increased by £1.7m to £5.4m

ANGLE plc ('ANGLE' or the 'Company'), the intellectual property and technology commercialisation company, is pleased to announce that following confirmation of preferred bidder status in February 2008, it has now been awarded the long term management contract of the London Development Agency's (LDA) Knowledge Connect Programme. 

In addition, it was originally announced that the value of this contract to ANGLE would be £3.7 million over three years. However, as a result of the LDA’s success in principle in securing European ERDF funds to support the programme, ANGLE is today pleased to announce that, subject to contract finalisation, the value of the Programme will be increased by £1.7 million to £5.4 million, once again over the next three years.

The Knowledge Connect Programme aims to increase the level of business research and development in London by creating new collaborations between business and the London knowledge base, with a focus on enterprises that have not previously worked with this sector.
 
This flagship Programme, a core part of the LDA’s Knowledge Transfer Strategy, will engage with a minimum of 2,880 businesses and involve ANGLE working intensively with more than 470 businesses across London. The Programme is being established to raise the performance and aspirations of London’s businesses by providing effective support for research and development, knowledge transfer and innovation across the Capital.
 
ANGLE was selected following a competitive tendering process on the basis of its experience in delivering similar business support programmes in London, UK wide and internationally. Additionally ANGLE has developed techniques which it was able to demonstrate have secured successful knowledge transfer from academic and research institutions across the World and that have measurable business benefits for a wide range of small and medium sized enterprises (SMEs).

Andrew Newland, Chief Executive of ANGLE, said:

"ANGLE's Management services business is a key feature of the Company's business model. The division provides top line revenue, is profitable and cash generative. However, it also provides the Company with access to leading academic, research and science organisations internationally, raising the profile of the whole Group and providing access to high quality IP commercialisation opportunities.

The award of this contract is not only a further success for our Management services business, but also underlines our strategy of focusing on long-term contracts that have the potential to generate significant revenues and earnings for the Group. We are delighted to be working on this project with not only the London Development Agency, but also more broadly with London's business and research communities to help identify new opportunities and secure business growth through knowledge transfer and innovation.”

Garth Selvey, Chairman of ANGLE, added: 

"This project adds to the strength of our Management services business, which provides the platform for the creation of real value in ANGLE's Progeny operation.

The Board believes that in the last five years ANGLE has generated significant inherent value in its underlying portfolio of companies, several of which are now at a stage of development to potentially deliver substantial cash returns for shareholders."

Enquiries:

ANGLE plc

01483 295830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Mark Connelly, Stewart Wallace

 

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

Buchanan Communications

Suzanne Brocks, James Strong

 

0207 466 5000

Notes to Editors

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE is an active investor in high growth companies in the medical and technology sectors in both the UK and the US, taking operational responsibility for the companies as subsidiaries during the development phase and maintaining a substantial shareholding and close involvement during the growth phase. ANGLE has significant holdings in 10 portfolio companies developing proven technologies targeting substantial commercial markets. ANGLE is listed on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKAORWRRBRUR
Date   Source Headline
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.